Eplerenone Reduces Mortality Risk in Mild Heart Failure Patients

 

November 17, 2010

Eplerenone (Inspra) is a steroid nucleus-based mineralcorticoid receptor (MR) antagonist with a higher degree of selectivity than spironolactone. The drug, by Pfizer, was compared to placebo and standard therapy in heart failure patients with mild symptoms in the EMPHASIS-HF trial.

The trial demonstrated a significant reduction in risk of cardiovascular death or heart failure hospitalizations.

In the trial, there was a higher incidence of hyperkalemia (elevated potassium) among patients assigned to eplerenone compared to placebo. However, hypokalemia (low potassium) was lower in the eplerenone group.

For more information: www.pfizer.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.